$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000121390024013414 Filed on February 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue	$1.173M	$1.240M	$469.8K
YoY Change	13.41%	163.99%	77.22%
Cost Of Revenue	$883.1K	$745.6K	$338.6K
YoY Change	4.96%	120.18%	120.54%
Gross Profit	$289.5K	$324.1K	$131.2K
YoY Change	50.36%	147.13%	17.58%
Gross Profit Margin	24.69%	26.14%	27.92%
Selling, General & Admin	$1.374M	$1.364M	$1.465M
YoY Change	-2.73%	-6.89%	-10.5%
% of Gross Profit	474.71%	420.79%	1116.84%
Research & Development	$656.8K	$609.8K	$851.4K
YoY Change	-25.22%	-28.37%	-66.44%
% of Gross Profit	226.89%	188.12%	649.08%
Depreciation & Amortization	$14.22K	$14.24K	$49.05K
YoY Change	-71.95%	-70.96%	-1.51%
% of Gross Profit	4.91%	4.39%	37.4%
Operating Expenses	$2.134M	$1.969M	$2.365M
YoY Change	-8.88%	-16.75%	-44.0%
Operating Profit	-$1.844M	-$1.645M	-$2.101M
YoY Change	-7.69%	-21.71%	-48.9%
Interest Expense	$73.30K	$226.7K	$136.0K
YoY Change	-52.02%	66.63%	1781.47%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.723M	-$1.478M	-$2.098M
YoY Change	-13.7%	-29.55%	-51.01%
Income Tax	$0.00	$0.00	$3.000K
% Of Pretax Income
Net Earnings	-$1.723M	-$1.478M	-$2.101M
YoY Change	-13.77%	-29.65%	-50.94%
Net Earnings / Revenue	-146.93%	-119.19%	-447.25%
Basic Earnings Per Share	-$0.18	-$0.19	-$0.91
Diluted Earnings Per Share	-$0.18	-$0.19	-$0.91
COMMON SHARES
Basic Shares Outstanding	6.057M shares	5.255M shares	936.8K shares
Diluted Shares Outstanding	9.613M shares	7.973M shares	2.301M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.644M	$9.579M	$11.50M
YoY Change	-20.77%	-16.67%	1.5%
Cash & Equivalents	$7.601M	$9.535M	$11.45M
Short-Term Investments	$43.09K	$44.46K	$43.05K
Other Short-Term Assets	$1.019M	$1.113M	$826.9K
YoY Change	46.53%	34.59%	488.52%
Inventory	$1.194M	$744.8K	$1.614M
Prepaid Expenses
Receivables	$207.7K	$372.9K	$81.65K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.06M	$11.81M	$14.02M
YoY Change	-15.02%	-15.75%	12.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.371M	$1.481M	$703.9K
YoY Change	82.01%	110.41%	-35.81%
Goodwill
YoY Change
Intangibles	$1.824M	$1.864M	$2.027M
YoY Change	-8.21%	-8.02%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$171.1K
YoY Change	-32.2%	-41.56%	56.74%
Total Long-Term Assets	$3.295M	$3.445M	$2.902M
YoY Change	14.1%	18.73%	-57.81%
TOTAL ASSETS
Total Short-Term Assets	$10.06M	$11.81M	$14.02M
Total Long-Term Assets	$3.295M	$3.445M	$2.902M
Total Assets	$13.36M	$15.26M	$16.92M
YoY Change	-9.31%	-9.84%	-12.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$402.6K	$306.5K	$770.8K
YoY Change	-45.4%	-60.24%	-54.84%
Accrued Expenses	$167.5K	$100.4K	$1.614M
YoY Change	-88.95%	-93.78%	-21.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.529M	$1.680M	$2.401M
YoY Change	-32.64%	-30.0%	-48.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$725.2K	$802.8K	$183.9K
YoY Change	896.35%	336.53%	-69.28%
Total Long-Term Liabilities	$725.2K	$802.8K	$183.9K
YoY Change	896.35%	336.53%	-69.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.529M	$1.680M	$2.401M
Total Long-Term Liabilities	$725.2K	$802.8K	$183.9K
Total Liabilities	$2.254M	$2.483M	$2.585M
YoY Change	-3.77%	-3.92%	-50.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.1M	-$105.4M	-$99.06M
YoY Change	5.97%	6.4%
Common Stock	$118.1M	$79.94M	$74.86M
YoY Change	52.17%	6.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.10M	$12.77M	$14.34M
YoY Change
Total Liabilities & Shareholders Equity	$13.36M	$15.26M	$16.92M
YoY Change	-9.31%	-9.84%	-12.71%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.723M	-$1.478M	-$2.101M
YoY Change	-13.77%	-29.65%	-50.94%
Depreciation, Depletion And Amortization	$14.22K	$14.24K	$49.05K
YoY Change	-71.95%	-70.96%	-1.51%
Cash From Operating Activities	-$5.957M	-$1.852M	-$2.713M
YoY Change	259.56%	-31.73%	-23.22%
INVESTING ACTIVITIES
Capital Expenditures	$9.290K	$9.290K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$500.0K
YoY Change	-100.0%	-100.0%	-246.38%
Cash From Investing Activities	-$9.290K	-$9.290K	-$500.0K
YoY Change	-92.75%	-98.14%	-263.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.654M	4.654M	5.315M
YoY Change	-7406.19%	-12.44%	-735.68%
NET CHANGE
Cash From Operating Activities	-5.957M	-1.852M	-2.713M
Cash From Investing Activities	-9.290K	-9.290K	-500.0K
Cash From Financing Activities	4.654M	4.654M	5.315M
Net Change In Cash	-1.312M	2.792M	2.102M
YoY Change	-29.03%	32.84%	-151.73%
FREE CASH FLOW
Cash From Operating Activities	-$5.957M	-$1.852M	-$2.713M
Capital Expenditures	$9.290K	$9.290K	$0.00
Free Cash Flow	-$5.966M	-$1.862M	-$2.713M
YoY Change	260.13%	-31.38%	-22.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022Q4	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2300526	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 310 - 815 W. Hastings Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
	dei	City Area Code CityAreaCode	(604)
	dei	Local Phone Number LocalPhoneNumber	669-7207
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6056970	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9534922	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8912517	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	44462	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	44422	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	372870	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	260399	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	744839	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1112977	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	498033	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11810070	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11331727	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1481102	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1864292	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104908	usd
CY2023Q4	us-gaap	Assets Assets	15255464	usd
CY2023Q2	us-gaap	Assets Assets	14106340	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1287623	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364190	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375713	usd
CY2023Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	28656	usd
CY2023Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	16171	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1680469	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2000619	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	802784	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15994	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2483253	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2016613	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5667970	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5667970	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3328191	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3328191	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	79936633	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	77620252	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38122231	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35741115	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105415222	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101400209	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12772211	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15255464	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14106340	usd
CY2023Q4	us-gaap	Revenues Revenues	1240200	usd
CY2022Q4	us-gaap	Revenues Revenues	469783	usd
	us-gaap	Revenues Revenues	2142062	usd
	us-gaap	Revenues Revenues	790571	usd
CY2023Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	745584	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	338620	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1533274	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	573654	usd
CY2023Q4	inm	Inventory Writedown InventoryWritedown	170474	usd
	inm	Inventory Writedown InventoryWritedown	263404	usd
	inm	Inventory Writedown InventoryWritedown	576772	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	324142	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	131163	usd
	us-gaap	Gross Profit GrossProfit	345384	usd
	us-gaap	Gross Profit GrossProfit	-359855	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	609791	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	851356	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1901884	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2230009	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1363958	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1464879	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2662689	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3025356	usd
CY2023Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55234	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	49049	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	110066	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	98097	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	59896	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	20237	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	11439	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-76554	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	1969087	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	2345047	usd
	us-gaap	Operating Expenses OperatingExpenses	4663200	usd
	us-gaap	Operating Expenses OperatingExpenses	5430016	usd
CY2023Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	166760	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	115797	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	302803	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	188384	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1478185	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2098087	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4015013	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5601487	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9800	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1478185	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2101087	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4015013	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5611287	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.54
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7973465	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2300526	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5650828	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1583073	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25191	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9578090	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4654042	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1478185	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18264	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12772211	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5322500	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	419	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3510200	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	116680	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11007940	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5357507	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	53	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2101087	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	70638	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14335051	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4015013	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5611287	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	110063	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98097	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	43455	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	187318	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	191909	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	197767	usd
	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	1019	usd
	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	418	usd
	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	978	usd
	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	2167	usd
	us-gaap	Inventory Write Down InventoryWriteDown	263404	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25085	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-608113	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-300576	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	614944	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	29706	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4908	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5507	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	112470	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18705	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-321106	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-508871	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12485	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16171	usd
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	193109	usd
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	209112	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4022346	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4968639	usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	500000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	21317	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21317	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9291	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9291	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-500000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4654042	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10744351	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4654042	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10744351	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	622405	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5275712	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6176866	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9534922	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11452578	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	9800	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3508749	usd
	us-gaap	Stock Issued1 StockIssued1	325699	usd
	us-gaap	Stock Issued1 StockIssued1	691483	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	968376	usd
	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Through December 31, 2023, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $4.0 million and $5.6 million for the six months ended December, 2023 and 2022, respectively. In addition, the Company had an accumulated deficit of approximately $105.4 million as of December 31, 2023. The Company expects to continue to generate operating losses for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash, cash equivalents and short-term investments of $9.5 million as of December 31, 2023, will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of calendar 2024, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the health and wellness sector as well as the level and timing of the Company’s operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.</p>
	us-gaap	Net Income Loss NetIncomeLoss	-4000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5600000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105400000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	9500000	usd
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities. During the three months and six months ended December 31, 2023, we adopted a change in presentation on our consolidated statements of operations loss in order to include foreign exchange loss in operating expenses. Prior periods have been revised to reflect this change in the presentation.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The preparation of financial statements in compliance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and warrant valuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><b><i> </i></b></p>
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2023Q4	us-gaap	Weighted Average Cost Inventory Amount WeightedAverageCostInventoryAmount	357224	usd
CY2023Q2	us-gaap	Weighted Average Cost Inventory Amount WeightedAverageCostInventoryAmount	93820	usd
CY2023Q4	us-gaap	Inventory Write Down InventoryWriteDown	170474	usd
	us-gaap	Inventory Write Down InventoryWriteDown	263404	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) or Canadian Deposit Insurance Corporation (“CDIC”) insurable limits. The Company has not experienced any losses related to these balances. The uninsured cash balance as of December 31, 2023, was $5.1 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 13.5pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s customers are primarily concentrated in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of December 31, 2023, the Company had three customers with an accounts receivable balance representing 57%, 28% and 11% of total accounts receivable, respectively. As of June 30, 2023, we had three customers with an accounts receivable balance representing 41%, 30% and 15% of total accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">For the three months ended December 31, 2023, the Company had two customers that accounted for 51% and 20% of revenue, respectively. For the three months ended December 31, 2022, the Company had four customers that accounted for 21%, 18%, 15% and 11% of revenue, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">For the six months ended December 31, 2023, the Company had four customers that accounted for 44%, 14%, 13% and 10% of revenue, respectively. For the six months ended December 31, 2022, the Company had four customers that accounted for 20%, 17%, 12%, and 10% of revenue, respectively. This change is reflective of the Company’s evolution to a primarily distributor model in 2023.</p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5100000	usd
	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	932954	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10264462	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3555456	shares
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	186980	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	514113	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	557859	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893506	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	744839	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2023Q4	us-gaap	Inventory Write Down InventoryWriteDown	170474	usd
	us-gaap	Inventory Write Down InventoryWriteDown	263404	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1124208	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	925321	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1481102	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2023Q4	us-gaap	Depreciation Depreciation	14242	usd
CY2022Q4	us-gaap	Depreciation Depreciation	8056	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	93085	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	90389	usd
	us-gaap	Depreciation Depreciation	28080	usd
	us-gaap	Depreciation Depreciation	16111	usd
CY2023Q4	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2023Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1063128	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	981141	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1864292	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	81986	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	81986	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	158935	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	158935	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	158935	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	158935	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	158935	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1069617	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1864292	usd
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	306455	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	544179	usd
CY2023Q4	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	356726	usd
CY2023Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	164587	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	101775	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	422221	usd
CY2023Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	542305	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	100446	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	357664	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1287623	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1248376	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.83
	inm	Preferred Investment Of Fair Value Options PreferredInvestmentOfFairValueOptions	1251449	usd
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1491138	usd
	inm	Fair Value Of Issuance Date FairValueOfIssuanceDate	1225230	usd
	inm	Investors Shares InvestorsShares	389000	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	usd
	us-gaap	Payments For Fees PaymentsForFees	560000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1252711	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	700000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	223881	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	51633	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.37
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0395	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.03	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102642	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	530400	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1357	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	631685	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.61
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	72418	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	559267	shares
CY2023Q4	inm	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestOutstandingWeightedAverageExercisePrice	0.5
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18264	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70638	usd
CY2023Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	10136	usd
CY2022Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	44042	usd
CY2023Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	8128	usd
CY2022Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	26596	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	109114	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	17889	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	78205	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	187634	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y6M
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	441004	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	361385	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	372227	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	125292	usd
CY2023Q4	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	132934	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1166974	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364190	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	802784	usd
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	May 14, 2027
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1095104	usd
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.0615	pure
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	968376	usd
CY2023Q4	us-gaap	Revenues Revenues	1240200	usd
CY2022Q4	us-gaap	Revenues Revenues	469783	usd
CY2023Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	745584	usd
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	338620	usd
CY2023Q4	us-gaap	Inventory Write Down InventoryWriteDown	170474	usd
CY2023Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1969087	usd
CY2022Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2345047	usd
CY2023Q4	us-gaap	Other Income OtherIncome	166760	usd
CY2022Q4	us-gaap	Other Income OtherIncome	112797	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1478185	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2101087	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	9534922	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11452578	usd
	us-gaap	Revenues Revenues	2142062	usd
	us-gaap	Revenues Revenues	790571	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1533274	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	573654	usd
	us-gaap	Inventory Write Down InventoryWriteDown	263404	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4663200	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5430016	usd
	us-gaap	Other Income OtherIncome	302803	usd
	us-gaap	Other Income OtherIncome	178584	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4015013	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5611287	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	9534922	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11452578	usd
CY2022Q4	inm	Cost Of Services Directs Materials CostOfServicesDirectsMaterials	1900000	usd
	us-gaap	Production Costs ProductionCosts	900000	usd
CY2023Q4	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44462	usd
CY2023Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44422	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	700	shares
CY2023Q4	us-gaap	Shares Issued SharesIssued	700	shares
CY2023Q2	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	300000	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q4	inm	Inventory Writedown InventoryWritedown		usd
CY2023Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1583073	shares
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities		usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2022Q4	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	41942
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3640
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
0001213900-24-013414-index-headers.html	Edgar Link	pending
0001213900-24-013414-index.html	Edgar Link	pending
0001213900-24-013414.txt	Edgar Link	pending
0001213900-24-013414-xbrl.zip	Edgar Link	pending
f10q1223ex31-1_inmed.htm	Edgar Link	pending
f10q1223ex31-2_inmed.htm	Edgar Link	pending
f10q1223ex32-1_inmed.htm	Edgar Link	pending
f10q1223ex32-2_inmed.htm	Edgar Link	pending
f10q1223_inmedpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
inm-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
inm-20231231_def.xml	Edgar Link	unprocessable
inm-20231231_lab.xml	Edgar Link	unprocessable
inm-20231231_pre.xml	Edgar Link	unprocessable
f10q1223_inmedpharma_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
inm-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2024 Q1 Form 10-Q Financial Statement

#000121390024013414 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2024 Q1 Form 10-Q Financial Statement

#000121390024013414 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm